Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

UFS professor addresses genetically modified food in South Africa in inaugural lecture

2016-09-23

Description: Chris Viljoen inaugural lecture Tags: Chris Viljoen inaugural lecture

At the inaugural lecture were, from the left front,
Prof Lis Lange, Vice Rector: Academic;
Prof Chris Viljoen; Prof Gert van Zyl,
Dean: Faculty of Health Sciences; back: Prof Marius Coetzee,
Head of Department of Haematology and Cell Biology;
and Dr Lynette van der Merwe, Undergraduate
Programme Director.
Photo: Stephen Collett

The first genetically modified (GM) crops in South Africa were planted in 1998. Eighteen years later, the country is one of the largest producers of GM food in the world. Those in support of genetically modified crops say this process is the only way to feed a rapidly growing world population. But those who criticise GM food describe it as a threat to the environment and safety of the population. Who is right? According to Prof Chris Viljoen of the Department of Haematology and Cell Biology at the University of the Free State, neither position is well-founded.

GM crops play a vital role in food security
While GM crops have an important role to play in increasing food production, the technology is only part of the solution to providing sufficient food for a growing world population. The major genetically modified crops produced in the world include soybean, cotton, maize and canola. However, the authenticity of food labelling and the long-term safety of GM food are issues that consumers are concerned about.

Safety and labelling of GM food important in South Africa
In his inaugural lecture on the subject “Are you really going to eat that?” Prof Viljoen addressed the importance of the safety and labelling of GM food in the country. “In order for food to be sustainable, production needs to be economically and environmentally sustainable. On the other hand, food integrity, including food quality, authenticity and safety need to be ensured,” Prof Viljoen said.

Labelling of food products for genetic modification was mandatory in South Africa, he went on to say. “It allows consumers the right of choice whether to eat genetically modified foods or not.” The Consumer Protection Act of 2008 requires food ingredients containing more than 5% of GM content to be labelled.

GMO Testing Facility world leader in food diagnostic testing
In 1999, Prof Viljoen spearheaded research in developing a GM diagnostic testing platform, and in 2003, a commercial diagnostic platform for GM status certification, called the GMO Testing Facility, was founded. The facility is a licensed Eurofins GeneScan laboratory a world leader in food diagnostic testing and provides diagnostic detection and quantification of genetically modified organisms (GMOs) in grain and processed foods for the local and international market.

Molecular diagnostic technology the future of food integrity, authenticity and safety
With GM labelling now well-established in South Africa, the next challenge is to establish the use of molecular diagnostic technology to ensure that food integrity, including food authenticity and safety is maintained, said Prof Viljoen.

“To the question ‘Are you really going to eat that?’ the answer is ‘yes’, but let’s continue doing research to make sure that what we eat is safe and authentic.”

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept